Hiperprolaktinemi ve erektil disfonksiyon
Prolaktin ön hipofizden sentezlenerek dolaşıma katılan bir hormondur. Prolaktinin aşırı salınımı erkeklerde başta infertilite ve erektil disfonksiyon (ED) olmak üzere birtakım bulgular ile karşımıza çıkabilmektedir. Hiperprolaktinemi nadir görülen bir durum olmasına karşın erkek cinsel fonksiyon bozukluğunun düzeltilebilir bir nedenidir. Hiperprolaktinemi saptanan hastalarda dopamin agonistleri ile yaklaşık %90 oranlarında tedavi mümkündür. Bu nedenle, özellikle testosteron düşüklüğü olan erektil disfonksiyonlu hastalarda serum prolaktin düzeyi ölçümü akılda tutulması gereken, önemli bir testtir. Sağlık Bilimleri Üniversitesi, Ankara Numune Eğitim ve Araştırma Hastanesi, Üroloji A Kliniği, Ankara, Türkiye
Hyperprolactinemia and erectile dysfunction
Prolactin is a hormone that is synthesized and released in systemic circulation from the anterior pituitary gland. Excessive prolactin release can be associated with some findings, especially loss of libido, infertility, and erectile dysfunction (ED) in men. Although hyperprolactinemia is a rare condition, it is a correctable cause of male sexual dysfunction. In patients with hyperprolactinemia, treatment is possible with dopamine agonists about 90% of the patients. Therefore, measurement of serum prolactin levels in patients with erectile dysfunction, especially those with low testosterone, is an important test that must be kept in mind.
___
- Becker KL, Kahn CR, Rebar RW. Prolactin and its disorders.
Chapter 13. Principles and Practice of Endocrinology and
Metabolism, 3rd ed. Philadelphia PA: Lippincott Williams &
Wilkins; 2002. p.37.
- Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and
management. Semin Reprod Med 2002;20:365–74. [CrossRef]
- Colao A, Savastano S. Medical treatment of prolactinomas. Nat
Rev Endocrinol 2011;7:267–78. [CrossRef]
- Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and
management. Treat Endocrinol 2003;2:23–32. [CrossRef]
- Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and
prolactinomas. Endocrinol Metab Clin North Am 2008;37:67–
99. [CrossRef]
- Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod
Med 1999;44(Suppl 12):1085–90.
- Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M,
Munson S, et al. Testosterone therapy in men with Parkinson disease:
results of the TEST-PD Study. Arch Neurol 2006;63:729. [CrossRef]
- Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance
ML, McCutcheon IE. The prevalence of pituitary adenomas: a
systematic review. Cancer 2004;101:613–9. [CrossRef] https://
doi.org/10.1002/cncr.20412
- Buvat J. Hyperprolactinemia and sexual function in men: a short
review. Int J Impot Res 2003;15:373–7. [CrossRef]
- Studer LH, Aylwin AS. Elevated prolactin levels among adult male
sex offenders. Psychol Rep 2006;98:841–8. [CrossRef]
- Bolyakov A, Paduch DA. Prolactin in men’s health and disease.
Curr Opin Urol 2011;21:527–34. [CrossRef]
- Zolbanin NM, Zolali E, Nayebi AM. Testosterone replacement
attenuates haloperidol-induced catalepsy in male rats. Adv Pharm
Bull 2014;4:237–41. [CrossRef]
- Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G,
et al. Effect of hyperprolactinemia in male patients consulting for
sexual dysfunction. J Sex Med 2007;4:1485–93. [CrossRef]
- Maggi M, Buvat J, Corona G, Guay A, Torres LO. Hormonal
causes of male sexual dysfunctions and their management
(hyperprolactinemia, thyroid disorders, GH disorders, and
DHEA). J Sex Med 2013;10:661–77. [CrossRef]
- Zeitlin SI, Rajfer J. Hyperprolactinemia and erectile dysfunction.
Rev Urol 2000;2:39–42.
- Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel
and newly approved antipsychotics on serum prolactin levels: a
comprehensive review. CNS Drugs 2014;28:421–53. [CrossRef]
- Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of
antipsychotic-induced hyperprolactinaemia on the hypothalamicpituitary-gonadal
axis. J Clin Psychopharmacol 2002;22:109–14.
[CrossRef]
- Berek JS. Prolaktin anomallikleri. Bölüm 5. Berek & Novak
Jinekoloji, 13. Baskı. Adana: Nobel Kitabevi; 2004. p.896.
- Holley JL. The hypothalamic-pituitary axis in men and women with
chronic kidney disease. Adv Chronic Kidney Dis 2004;11:337–41.
[CrossRef]
- Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D,
Rebar R, et al. Guidelines for the diagnosis and treatment of
hyperprolactinemia. J Reprod Med 1999;44(Suppl 12):1075–84.
- Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high
molecular mass forms of circulating prolactin. Ann Clin Biochem
2005;42:175–92. [CrossRef]
- Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008;11:141–
6. [CrossRef]
- Hattori N, Aisaka K, Shimatsu A. A possible cause of the variable
detectability of macroprolactin by different immunoassay systems.
Clin Chem Lab Med 2016;54. [CrossRef]
- Green AI, Sherlock M, Stewart PM, Gittoes NJ, Toogood AA.
Extensive experience in the management of macroprolactinomas.
Clin Endocrinol (Oxf) 2014;81:85–92. [CrossRef]
- Sadideen H, Swaminathan R. Macroprolactin: what is it and what
is its importance? Int J Clin Pract 2006;60:457–61. [CrossRef]
- Whyte MB, Pramodh S, Srikugan L, Gilbert JA, Miell JP, Sherwood
RA, et al. Importance of cannulated prolactin test in the definition
of hyperprolactinaemia. Pituitary 2015;18:319–25. [CrossRef]
- Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Longterm
follow-up of patients with hyperprolactinaemia. Clin Endocrinol
(Oxf) 1996;45:299–303. [CrossRef]
- Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB.
Transsphenoidal microsurgical therapy of prolactinomas: initial
outcomes and long-term results. Neurosurgery 1999;44:254–61.
[CrossRef]
- Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of
hyperprolactinemia. CMAJ 2003;169:575–81.
- Iglesias P, Díez JJ. Macroprolactinoma: a diagnostic and therapeutic
update. QJM 2013;106:495–504. [CrossRef]
- Harisaran V, Cone E, Hwang K. Specific Endocrinopathies and
Male Infertility. In: Kavoussi PK, et al., editors. Clinical Urologic
Endocrinology. London: Springer-Verlag; 2013. p.123–37.
- Van’t Verlaat JW, Croughs RJM. Withdrawal of bromocriptine
after long-term therapy for macroprolactinomas: effect on plasma
prolactin and tumour size. Clin Endocrinol (Oxf)1991;34:175–8.
[CrossRef]
- Webster J. Clinical management of prolactinomas. Best Pract Res
Clin Endocrinol Metab 1999;13:395–408. [CrossRef]
- Xue XC, Jiang S, Yin SL, Zhong CH, Zhou PZ, Cheng SW. Effects
of bromocriptine on the treatment of prolactinomas in male
patients and its influences on their sexual function. Sichuan Da
Xue Xue Bao Yi Xue Ban 2013;44:452–7
- Colao A, Lombardi G, Annunziato L. Cabergoline. Exp Opin
Pharmacother 2000;1:555–74. [CrossRef]
- Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe
M, Velkeniers B, et al. Cabergoline in the treatment of
hiperprolactinemia: a study in 455 patients. J Clin Endocrinol
Metab 1999;84:2518–22. [CrossRef]
- Nickel M, Moleda D, Loew T, Rother W, Pedrosa Gil F. Cabergoline
treatment in men with psychogenic erectile dysfunction: a
randomized, double-blind, placebo-controlled study. Int J Impot
Res 2007;19:104–7. [CrossRef]
- Arduc A, Gokay F, Isik S, Ozuguz U, Akbaba G, Tutuncu Y, et al.
Retrospective comparison of cabergoline and bromocriptine effects
in hyperprolactinemia: a single center experience. J Endocrinol
Invest 2015;38:447–53. [CrossRef]
- Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R,
Cerbone G, et al. The effect of quinagolide and cabergoline, two
selective dopamine receptor type-2 agonists, in the treatment of
prolactinomas. Clin Endocrinol (Oxf) 2000;53:53–60. [CrossRef]
- Kvistborg A, Halse J, Bakke S, Bjøro T, Hansen E, Djøseland O,
et al. Long-term treatment of macroprolactinomas with CV 205–
502. Eur J Endocrinol 1993;128:301–7. [CrossRef]
- Glezer A, Bronstein MD. Prolactinomas. Endocrinol Metab Clin
North Am 2015;44:71–8. [CrossRef]
- Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ,
Woodmansee WW, Laws ER. Current indications for the surgical
treatment of prolactinomas. J Clin Neurosci 2015;22:1785–91.
[CrossRef]
- Wolfsberger S, Czech T, Vierhapper H, Benavente R, Knosp E.
Microprolactinomas in males treated by transsphenoidal surgery.
Acta Neurochir (Wien) 2003;145:935–40; discussion 940–1.
[CrossRef]
- Passos VQ, Souza JJS, Musolino NRC, Bronstein MD.
Long-term follow-up of prolactinomas: normoprolactinemia
after bromocriptine withdrawal. J Clin Endocrinol Metab
2002;87:3578–82. [CrossRef]